Answers are grounded in this paper and cite their sources.
Dheda et al. [1] evaluated the performance of a newly developed blood test (T-SPOT.TB) for diagnosing latent tuberculosis infection (LTBI) in HIV-infected patients. The in-vitro test detects the IFN-γ response of peripheral blood mononuclear cells (PBMC) to Mycobacterium tuberculosis-specific antigens (ESAT-6, CFP-10) using an enzyme-linked immunospot assay. In contrast to the conventional tuberculin skin test (TST), the new test includes a positive control based on mitogen stimulation to signal the technical reliability of the results. In order to evaluate the performance of the T-SPOT.TB in HIV-infected individuals by impaired immune response, Dheda et al. [1] compared the quantitative results of the positive control reactions in HIV-negative and HIV-positive patients. In general, both groups had a similar response to the mitogen stimulation (P = 0.5), but the response to mitogen stimulation was significantly reduced (P = 0.04) in HIV-positive patients with a CD4 cell count less than 200 cells/μl. One patient had no stimulation of the positive control. Martin et al. [2] found 24 positive T-SPOT.TB tests in a cohort of 100 HIV-positive individuals with active tuberculosis or at increased risk of tuberculosis infection. They described a negative correlation between the number of ESAT-6/CFP-10 spots and the absolute CD4 cell count. In a small study conducted by the Swiss HIV Cohort Study in Bern and St Gallen, we compared 46 HIV-positive patients from a non-endemic area (Switzerland, 76% male, median age 44 years, CD4 cells 26% lymphocytes) with 39 HIV-positive patients from a tuberculosis endemic area (sub-Saharan origin, 39% male, age 33 years, CD4 cells 23%). In both groups the conventional TST (Tuberculin PPD RT 23; Pro Vaccine, Baar, Switzerland) and the new T-SPOT.TB (Oxford Immunotec, Oxford, UK) were performed. Eight T-SPOT.TB-tests (9.4%) were indeterminate with an insufficient positive control [≤ 20 spot-forming cells (SFC)/250 000 PBMC, range 1–15], all of them showed a negative TST result. Seven patients had a CD4 cell count greater than 200 cells/μl, and mean CD4 cell counts from all eight patients did not differ from patients with a valid positive control (451 versus 433 cells/μl; P = 0.75). We found no significant correlation between the CD4 cell count and positivity in mitogen stimulation. The median mitogen-stimulated SFC in patients with a CD4 cell count of less than 200 cells/μl was 347 SFC/106 PBMC versus 503 SFC/106 PBMC in patients with a CD4 cell count greater than 200 cells/μl (P = 0.27; Fig. 1).Fig. 1: Mitogen (phytohaemagglutinin) responses in HIV-infected individuals stratified by absolute CD4 cell count. The magnitude of spot-forming cells after the mitogen stimulation in HIV-positive individuals with an absolute CD4 cell count of less than 200 cells/μl compared with individuals with a CD4 cell count greater than 200 cells/μl. We did not find significantly different responses in the two groups. Groups were compared using the Mann–Whitney U-test. PBMC, Peripheral blood mononuclear cell; PHA, phytohaemagglutinin; SFC, spot-forming cell.None of the 40 Swiss patients (0%) tested positive by T-SPOT.TB or TST, whereas nine of the 37 eligible T-SPOT.TB (24%) were positive in the group with a high probability of previous tuberculosis exposure. In five patients from the latter group (14%) the TST was also positive (above 5 mm). The inter-test agreement by kappa statistic was κ = 0.69. We did not find a significant correlation between the ESAT-6 or CFP-10 spot numbers per 106 PBMC and the absolute CD4 cell count. Individuals with positive test results in both tests had a significantly higher absolute CD4 cell count than individuals with a positive T-SPOT.TB and negative TST (P = 0.014). The main problem with evaluating a new diagnostic procedure for LTBI diagnosis is the lack of a gold standard. TST can yield false-positive results in bacillus Calmette–Guérin-vaccinated patients. In HIV-infected individuals, skin anergy can reduce the sensitivity of TST in latently infected individuals. We therefore decided to use lifetime exposure to tuberculosis in an endemic area as a proxy for LTBI. Previous studies found a prevalence of LTBI in individuals from sub-Saharan Africa of 35% [3]. When historic prevalence rates were used as a gold standard, the sensitivity of the new T-cell-based assay was 70% compared with 40% for the conventional TST. Our data therefore suggest a higher sensitivity and more accurate diagnosis of LTBI in HIV-infected patients by the T-SPOT.TB than the conventional TST. In contrast to Dheda et al. [1] we found a higher rate of indeterminate test results (9 versus 3%). In these cases the differentiation between anergic T-SPOT.TB results and technical failures is difficult. In our experience, indeterminate results were not associated with CD4 cell count, making a biological basis for the failures less likely. Our results support the conclusion of Dheda et al. [1] and Martin et al. [2] that a T-cell-based assay is sensitive enough to detect LTBI in even immunocompromised patients with HIV infection. Our study confirms the good test performance in patients with low CD4 cell counts. Acknowledgements The members of the Swiss HIV Cohort Study are M. Battegay, E. Bernasconi, J. Böni, H. Bucher, Ph. Bürgisser, S. Cattacin, M. Cavassini, R. Dubs, M. Egger, L. Elzi, P. Erb, M. Fischer, M. Flepp, A. Fontana, P. Francioli (President of the SHCS, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne), H. Furrer (Chairman of the Clinical and Laboratory Committee), M. Gorgievski, H. Günthard, H. Hirsch, B. Hirschel, I. Hösli, Ch. Kahlert, L. Kaiser, U. Karrer, O. Keiser, C. Kind, Th. Klimkait, B. Ledergerber, G. Martinetti, B. Martinez, N. Müller, D. Nadal, M. Opravil, F. Paccaud, G. Pantaleo, L. Perrin, M. Rickenbach (Head of Data Center), C. Rudin (Chairman of the Mother and Child Substudy), P. Schmid, D. Schultze, J. Schüpbach, R. Speck, P. Taffé, P. Tarr, A. Telenti, A. Trkola, P. Vernazza (Chairman of the Scientific Board), R. Weber and S. Yerly. Sponsorship: This study was financed in the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (project 395).
No takes yet. Share an insight, caveat, or question.
Hoffmann et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: